Search Results - recombinant+immunotoxin

4 Results

Sort By:

Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma

Abstract: Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Dimiter Dimitrov

Keywords(s): ADC, ANTIBODY, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-2, GPC2, Immunotoxin, Neuroblastoma, Recombinant Immunotoxin, Rit

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers

Abstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Bryan Fleming

Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

High Affinity Monoclonal Antibodies Targeting Glypican-1

Abstract: Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li

Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-1, GPC1, HO, Immunotoxin, NANOBODY, Pancreatic Cancer, Recombinant Immunotoxin, Rit, Single Domain Antibody

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics

New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity

Abstract: Recombinant immunotoxins (RITs) constitute a promising solution to hematologic cancers (e.g., Multiple Myeloma [MM]). RITs are chimeric proteins composed of a targeting domain fused to a bacterial toxin. Upon binding to a cancer cell displaying the target antigen, RITs are internalized, metabolized and the released toxin kills the cell. While...

Published: 5/21/2024 | Inventor(s): Ira Pastan

Keywords(s): Abd, Albumin Binding Domain, antibody conjugate, B-cell Maturation Antigen, BCMA, Hematologic Cancer, Mm, MULTIPLE MYELOMA, Pastan, Recombinant Immunotoxin, Rit

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology